Encouraging trial results for Daiichi anti-stroke therapy

Daiichi Sankyo's Lixiana (edoxaban) has announced positive results from the ENGAGE AF-TIMI 48 trial, with the drug reducing the likelihood of intercranial haemorrhage (ICH) among patients suffering from atrial fibrillation (AF).